Tower Research Capital LLC TRC Cuts Stake in Smith & Nephew plc (NYSE:SNN)

Tower Research Capital LLC TRC decreased its stake in Smith & Nephew plc (NYSE:SNN) by 53.9% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 1,016 shares of the medical equipment provider’s stock after selling 1,187 shares during the period. Tower Research Capital LLC TRC’s holdings in Smith & Nephew were worth $28,000 as of its most recent SEC filing.

Other large investors have also modified their holdings of the company. CWM LLC boosted its holdings in Smith & Nephew by 68.6% in the 4th quarter. CWM LLC now owns 954 shares of the medical equipment provider’s stock worth $26,000 after acquiring an additional 388 shares during the period. Argonautica Private Wealth Management Inc. lifted its position in shares of Smith & Nephew by 4.5% during the fourth quarter. Argonautica Private Wealth Management Inc. now owns 10,362 shares of the medical equipment provider’s stock worth $283,000 after purchasing an additional 449 shares in the last quarter. Highland Capital Management LLC boosted its stake in shares of Smith & Nephew by 1.8% in the fourth quarter. Highland Capital Management LLC now owns 24,915 shares of the medical equipment provider’s stock valued at $680,000 after purchasing an additional 450 shares during the period. National Bank of Canada FI grew its holdings in Smith & Nephew by 36.0% during the 4th quarter. National Bank of Canada FI now owns 1,967 shares of the medical equipment provider’s stock valued at $53,000 after purchasing an additional 521 shares in the last quarter. Finally, EverSource Wealth Advisors LLC increased its stake in Smith & Nephew by 75.0% during the 4th quarter. EverSource Wealth Advisors LLC now owns 1,227 shares of the medical equipment provider’s stock worth $33,000 after buying an additional 526 shares during the period. Institutional investors and hedge funds own 25.64% of the company’s stock.

Analyst Ratings Changes

Separately, StockNews.com upgraded Smith & Nephew from a “buy” rating to a “strong-buy” rating in a research note on Friday, March 15th. Three investment analysts have rated the stock with a hold rating, two have issued a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy”.

Smith & Nephew Stock Performance

Shares of Smith & Nephew stock traded up $0.34 on Friday, hitting $24.78. 1,063,758 shares of the company’s stock traded hands, compared to its average volume of 1,109,205. Smith & Nephew plc has a 52-week low of $21.52 and a 52-week high of $32.71. The company has a debt-to-equity ratio of 0.44, a quick ratio of 0.72 and a current ratio of 1.77. The firm’s 50-day moving average is $25.57 and its 200 day moving average is $26.01.

Smith & Nephew Announces Dividend

The business also recently disclosed a semi-annual dividend, which will be paid on Wednesday, May 22nd. Shareholders of record on Tuesday, April 2nd will be issued a dividend of $0.462 per share. This represents a yield of 2.8%. The ex-dividend date of this dividend is Monday, April 1st.

Smith & Nephew Profile

Smith & Nephew plc, together with its subsidiaries, develops, manufactures, markets, and sells medical devices and services in the United Kingdom and internationally. It operates through three segments: Orthopaedics, Sports Medicine & ENT, and Advanced Wound Management. The company offers knee implant products for knee replacement procedures; hip implants for revision procedures; trauma and extremities products that include internal and external devices used in the stabilization of severe fractures and deformity correction procedures; and other reconstruction products.